This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Primary endpoint1

Efficacy:

  • All-cause mortality from first dose of study drug to Day 42 in the ITT population​​​​​​​

Secondary endpoints

Efficacy:

  • Overall response at end of treatment in the mITT population

Other Secondary endpoints:

  • All-cause mortality from first dose of study drug to Day 84
  • Overall clinical, mycological and radiological responses on Day 42, 84 and end of treatment†
  • Safety
  • Tolerability

* Hepatic dysfunction (bilirubin ≥3 × ULN, alanine transaminase or aspartate transaminase ≥5 × ULN, cirrhosis or chronic hepatic failure), or moderate-to-severe renal dysfunction (calculated creatinine clearance <50 mL/min). †As assessed by the data review committee. ITT, intention-to-treat; IV, intravenous; mITT, modified intention-to-treat; PO, orally; q8h, every 8 hours; q12h, every 12 hours; q24h every 24 hours; ULN- upper limit of normal

Explore more

Dosing

Access dosing information

Prescribing Information for Cresemba (isavuconazole)

Great Britain
Cresemba (isavuconazole) 100mg hard capsules
Cresemba (isavuconazole) 200mg powder for concentrate for solution for infusion 

Northern Ireland
Cresemba (Isavuconazole) 100mg hard capsules and Cresemba (Isavuconazole) 200mg powder for concentrate for solution for infusion

Prescribing Information for Vfend (voriconazole)
​​​​​​​
Great Britain
​​​​​​​​​​​​​​Vfend (voriconazole) 50mg film coated tablets
Vfend (voriconazole) 200mg film coated tablets
Vfend (voriconazole) 200mg powder for solution for infusion
Vfend (voriconazole) 40mg/ml powder for oral suspension

Northern Ireland
​​​​​​​​​​​​​​Vfend (voriconazole): 50mg film coated tablets, 200mg film coated tablets & 40mg/ml powder for oral suspension 

References:
  1. ​​​​​​​Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voricanazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE); a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–769.
PP-CRB-GBR-1202. August 2021

Invasive Aspergillosis (Quick Links)

Safety Profile

 CRESEMBA safety information

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?